Number of pages: 100 | Report Format: PDF | Published date: March 10, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
According to the deep-dive market assessment study by Growth Plus Reports, the global metastatic soft tissue sarcoma therapeutics market was valued at US$ 700 million in 2022 and is expected to register a revenue CAGR of 5.8% to reach US$ 1,162.7 million by 2031.
Metastatic Soft Tissue Sarcoma Therapeutics Market Fundamentals
Metastatic soft tissue sarcoma is a rare and aggressive type of cancer that arises from soft tissues, such as muscles, fat, nerves, and blood vessels. The global metastatic soft tissue sarcoma therapeutics market is relatively small compared to other types of cancer, with several treatment options available. The main treatment options for metastatic soft tissue sarcoma include surgery, radiation therapy, chemotherapy, targeted therapy, and immunotherapy. Surgery is often the first line of treatment for soft tissue sarcoma that has not spread to other body parts. Radiation therapy can also be used to shrink tumors and relieve symptoms.
Chemotherapy kills cancer cells that have spread to other parts of the body. Targeted therapy is a newer treatment that targets specific proteins in cancer cells. At the same time, immunotherapy works by boosting the immune system to fight cancer cells. Olaratumab, in combination with doxorubicin, represents a new potential first-line treatment option. Second-line therapy is often histology-driven, and novel treatment options include trabectedin and eribulin. Patients with metastatic soft tissue sarcoma can achieve positive outcomes and improve their quality of life with proper treatment and management.
Several companies, including Pfizer, Eli Lilly and Company, Novartis, and Eisai, offer metastatic soft tissue sarcoma treatments. The market for these treatments is relatively small, with estimated global sales of around $500 million in 2020.
Despite the challenges in treating metastatic soft tissue sarcoma, ongoing efforts exist to develop new, more effective therapies. Clinical trials are underway for various treatments, including immunotherapies and combination therapies that target multiple pathways involved in the growth and spread of soft tissue sarcoma.
Metastatic Soft Tissue Sarcoma Therapeutics Market Dynamics
The global metastatic soft tissue sarcoma market is growing rapidly. It is expected to continue to do so in the coming years. Although metastatic soft tissue sarcoma is a rare type of cancer, the incidence and prevalence of this disease are increasing globally. In 2022, an estimated 13,190 people (7,590 males and 5,600 females) were diagnosed with soft-tissue sarcoma, and 5,130 deaths (2,740 men and 2,390 women) from this disease occurred in the United States. About 15% of sarcomas were found in the metastatic stage. The 5-year survival rate for people with metastatic sarcoma is 16%. This has led to an increase in the demand for effective treatment options. With a high demand for treatment options, the market is seeing more research and development to find new and innovative therapies that can effectively target this disease. Key trends in the market include the development of personalized medicine and targeted therapies, as well as an increased focus on early detection and prevention. As the market evolves, stakeholders must stay abreast of the latest trends and developments to make informed treatment and investment strategy decisions. Governments worldwide are taking initiatives to improve cancer care and increase funding for cancer research. This has led to the development of new therapies and improved access to existing therapies, contributing to the revenue growth of the metastatic soft tissue sarcoma therapeutics market.
However, side effects associated with cancer treatment, the high cost of treatment, stringent government regulations, and high failure rate in clinical trials hinder the global metastatic soft tissue sarcoma market revenue growth to some extent. Moreover, the lack of reimbursement for most registered drugs under the public insurance programs and the non-availability of many oncology drugs in some regions might hamper future market revenue growth.
Metastatic Soft Tissue Sarcoma Therapeutics Market Ecosystem
The global metastatic soft tissue sarcoma therapeutics market has been analyzed from three perspectives: therapy type, drug type, and region.
Metastatic Soft Tissue Sarcoma Therapeutics Market by Therapy Type
Based on therapy type, the global metastatic soft tissue sarcoma therapeutics market has been segmented into monotherapy and combination therapy.
The combination therapy accounts for the largest revenue share in the global metastatic soft tissue sarcoma therapeutics market. Combination therapy involves the usage of two or more chemotherapy drugs. Compared to monotherapy, combined chemotherapy is often used to achieve a better response rate and improve overall survival. Several clinical trials have evaluated the effectiveness of combination chemotherapy versus monotherapy for treating metastatic soft tissue sarcoma. These trials have shown that combination chemotherapy generally provides better outcomes than monotherapy, including higher response rates, longer progression-free, and overall survival. For instance, the FDA approved olaratumab combined with doxorubicin, especially as there was an improved overall survival (OS) and response rate (ORR).
Metastatic Soft Tissue Sarcoma Therapeutics Market by Drug Type
Based on drug type, the global metastatic soft tissue sarcoma therapeutics market has been segmented into doxorubicin, olaratumab, irinotecan, pazopanib, atezolizumab, and others.
The doxorubicin segment accounts for the largest revenue share in the global metastatic soft tissue therapeutics market. Doxorubicin is currently a key drug used to treat metastatic soft tissue sarcoma. Doxorubicin monotherapy and combination chemotherapy containing doxorubicin are options for treating advanced or metastatic soft tissue sarcoma.
The olaratumab segment is projected to reach a significant revenue CAGR during the forecast period. Olaratumab, a monoclonal antibody that targets PDGFR-α, was the first agent to be combined with doxorubicin and demonstrated an OS benefit in patients with metastatic soft tissue sarcoma. Olaratumab targets PDGFR-α by blocking the binding of PDGF ligands and preventing receptor activation.
Metastatic Soft Tissue Sarcoma Therapeutics Market by Region
Based on region, the global metastatic soft tissue sarcoma therapeutics market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
North America has the largest revenue share in the global metastatic soft tissue sarcoma therapeutics market. The market in North America is a dynamic and promising area of healthcare. With the latest advancements in research and the development of therapeutic options, there is renewed hope for patients suffering from this disease. The market is expected to grow rapidly in the coming years, driven by increasing patient awareness and improved access to treatment options. This growth is expected to be fueled by innovative therapies targeting tumor-specific molecular pathways and efforts to optimize existing treatment regimens.
Europea stood second in the metastatic soft tissue sarcoma therapeutics market, is highly competitive, and rapidly evolving. Immunotherapy is one of the most promising therapies for mrtastatic soft tissue sarcoma, which uses the immune system to fight cancer. Several immunotherapy drugs have been approved for the treatment of mSTS in Europe, including pembrolizumab (Keytruda), nivolumab (Opdivo), and ipilimumab (Yervoy). In addition to immunotherapy, other targeted therapies are also being developed for mSTS. These therapies aim to target specific genetic mutations or pathways that drive the growth of cancer cells. For instance, olaratumab (Lartruvo) is a monoclonal antibody targeting the platelet-derived growth factor receptor alpha (PDGFR-alpha), commonly mutated in metastatic soft tissue sarcoma. Chemotherapy is also an important treatment option for metastatic soft tissue sarcoma. However, traditional chemotherapy drugs have limited efficacy and can cause severe side effects. To overcome these limitations, researchers are developing new chemotherapy agents that are more effective and less toxic. For instance, trabectedin (Yondelis) is a chemotherapy drug that has shown promising results in clinical trials for metastatic soft tissue sarcoma.
Asia Pacific is projected to gain a significant revenue CAGR in the metastatic soft tissue sarcoma therapeutics market during the forecast period due to its large population and increase in the incidence of soft tissue sarcoma. Major regional market players include Novartis International AG, Eli Lilly and Company, Pfizer Inc., Merck & Co., Inc., and Bristol-Myers Squibb Company. These companies are focusing on developing new and effective therapies for metastatic soft tissue sarcoma to cater to the increasing demand in the region.
Metastatic Soft Tissue Sarcoma Therapeutics Market Competitive Landscape
The prominent players operating in the global metastatic soft tissue sarcoma therapeutics market are:
Metastatic Soft Tissue Sarcoma Therapeutics Market Strategic Developments
The global metastatic soft tissue sarcoma therapeutics market is expected to grow at a revenue CAGR of 5.8% during the forecast period.
GlaxoSmithKline Plc, Eli Lilly & Company, Bayer AG, Eisai Pharmaceuticals Pvt Ltd., and Merck & Company Inc. are among the key players in the global metastatic soft tissue sarcoma therapeutics market.
The combination therapy segment accounts for the largest revenue share in the global metastatic soft tissue sarcoma therapeutics market.
Asia Pacific is expected to observe the highest revenue growth in the global metastatic soft tissue sarcoma therapeutics market during the forecast period.
The global metastatic soft tissue sarcoma therapeutics market was valued at US$ 700 million in 2022.
*Insights on financial performance are subject to the availability of information in the public domain